Considering a switch from Mounjaro to Wegovy is a significant decision in a weight management plan. This guide provides an objective, evidence-based overview to help individuals, in consultation with their clinician, make an informed choice based on clinical data and practical considerations.

Key Reasons for Switching From Mounjaro to Wegovy

The primary reason many UK patients explore switching from Mounjaro (tirzepatide) to Wegovy (semaglutide) is long-term treatment viability, often influenced by cost. Both are GLP-1 receptor agonist medications indicated for weight management, but a divergence in their pricing has impacted accessibility for continuous therapy.

A price adjustment for Mounjaro in late 2025 created a notable cost difference, positioning Wegovy as a more financially sustainable option for the ongoing treatment required to maintain weight loss for many individuals.

Financial Considerations in Weight Management

In late 2025, a significant price increase for Mounjaro was announced, reportedly leading some suppliers to see a substantial rise in enquiries for Wegovy.

For individuals in the UK, this pricing shift has tangible financial implications. For example, Wegovy's starting dose is priced at approximately £85 per month, while higher doses of Mounjaro were reported to cost up to £325 after 1 September 2025. This economic factor has prompted both patients and clinicians to re-evaluate treatment plans, balancing clinical efficacy with affordability.

The consideration is not a single cost, but the cumulative expense over the months or years required for effective weight management. A sustainable treatment plan must be financially manageable for the individual over the long term.

Comparing Clinical Efficacy and Mechanisms

While cost is a significant factor, the decision to switch is also supported by robust clinical evidence demonstrating Wegovy's efficacy. Both medications function by mimicking the GLP-1 hormone, which helps regulate appetite, but they have distinct pharmacological mechanisms.

Understanding the clinical profiles of these two medications is essential for an informed discussion with a healthcare provider.

Mounjaro vs Wegovy: A Clinical Snapshot

This table highlights that while both are effective, they have different mechanisms and have shown different average outcomes in their respective clinical trials. Both, however, produce clinically significant weight loss.

Here is a more detailed explanation:

• Mounjaro (Tirzepatide): As a dual-agonist, it activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual mechanism of action is a distinguishing feature. You can learn more about its function in our guide on how Mounjaro works.
• Wegovy (Semaglutide): This medication is a single-agonist, focusing its action on the GLP-1 receptor.

Despite this difference, clinical trials for Wegovy have consistently demonstrated substantial weight loss. While some head-to-head studies indicate that tirzepatide may lead to a greater average weight loss than semaglutide at currently approved doses, Wegovy remains a highly effective option.

For many individuals, the weight loss achieved with Wegovy is sufficient to meet their health goals, particularly when considering the difference in cost. A consultation with a clinician will involve weighing the potential for greater average efficacy with Mounjaro against the significant cost savings and proven, substantial results of Wegovy, making the switch a practical and medically sound option for many people in the UK.

Key Clinical Considerations Before You Switch

The decision to switch from Mounjaro to Wegovy is a medical one that must be made under the guidance of a qualified clinician. A thorough consultation is essential to ensure the transition is safe and appropriate for your individual health circumstances.

A critical part of this discussion is determining eligibility for Wegovy based on UK guidelines. Wegovy is licensed for individuals with a Body Mass Index (BMI) of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity (such as high blood pressure or high cholesterol).

A common question arises: what if Mounjaro treatment has already reduced an individual's BMI below these thresholds? This does not typically preclude a switch. Clinicians recognise the importance of continued treatment to prevent weight regain and can justify continuing therapy to maintain the health benefits achieved.

Reviewing Your Medical and Treatment History

A comprehensive review of your medical history is a crucial safety measure. Your clinician needs a complete understanding of your health to determine if Wegovy is a suitable and safe alternative.

This review will include:

• Pre-existing Conditions: It is vital to disclose any history of pancreatitis, thyroid issues (specifically medullary thyroid carcinoma or a family history of Multiple Endocrine Neoplasia syndrome type 2), or severe gastrointestinal diseases.
• Current Medications: Your clinician will assess for potential interactions between Wegovy and any other medications, including prescription drugs, over-the-counter products, and supplements.
• Your Experience with Mounjaro: How you responded to Mounjaro provides valuable data. If you experienced significant side effects, this information helps your clinician anticipate your potential response to Wegovy and plan a more cautious transition.

An open and honest dialogue about your health is fundamental to a safe medication switch. This information enables your clinician to develop a personalised transition plan that minimises risks and supports continued success.

Details about your Mounjaro treatment—such as your current dose, duration of use, and any side effects—are valuable clinical information. If you tolerated Mounjaro well, it suggests a potentially smooth adaptation to Wegovy. Conversely, if you experienced persistent nausea, your clinician might recommend a slower dose titration for Wegovy to improve tolerability.

Setting Realistic Expectations for Efficacy and Side Effects

It is important to approach the switch with realistic expectations. While both medications are effective for weight loss, they are not identical. Mounjaro's dual-agonist mechanism (GIP and GLP-1) differs from Wegovy's single-agonist mechanism (GLP-1), which may lead to a different physiological response.

Discussing potential outcomes with your clinician will help set expectations. For most individuals, weight loss can be effectively maintained or continued after the switch. Clinical trials for Wegovy demonstrated an average weight loss of approximately 15% of body weight over 68 weeks in participants using the 2.4mg maintenance dose.

However, some changes may be observed during the transition:

• Appetite Sensation: The subjective feeling of appetite suppression may differ from your experience with Mounjaro.
• Side Effects: A temporary recurrence of mild side effects, such as nausea or gastrointestinal changes, is possible as your body adjusts to the new medication, even if you were stable on Mounjaro.
• Weight Fluctuation: A brief weight plateau or minor fluctuation is a normal part of the adjustment period.

Ultimately, this is a collaborative medical decision made between you and your clinician. The objective is to establish a partnership focused on creating a safe, effective, and sustainable plan for your long-term health.

How to Switch from Mounjaro to Wegovy Safely

The process of switching from Mounjaro to Wegovy is a well-established clinical practice. The transition is managed carefully by a clinician to maintain the continuity of your weight management plan while prioritising safety.

The primary goal is to transition from tirzepatide (the active ingredient in Mounjaro) to semaglutide (the active ingredient in Wegovy) with minimal disruption and side effects.

A key component of this process is the "washout" period—a planned interval between the last dose of Mounjaro and the first dose of Wegovy. A 7-day gap is typically recommended. This allows time for the concentration of Mounjaro in the body to decrease before introducing Wegovy, which helps to minimise the potential for cumulative side effects like nausea.

This flowchart illustrates the standard, safety-focused clinical approach for planning a medication switch.

As shown, each step, from reviewing your medical history to determining the appropriate starting dose, is tailored to your individual circumstances.

What Will My Starting Dose of Wegovy Be?

This is a frequent and important question. Your clinician will not perform a direct dose conversion from Mounjaro. Instead, your individual experience with Mounjaro will inform the decision for a safe and appropriate starting dose of Wegovy. In most cases, this involves starting at a low dose to allow your body to acclimatise.

For example, an individual who was stable on a mid-to-high dose of Mounjaro (e.g., 7.5mg or 10mg) would not begin Wegovy at its highest dose. A clinician might recommend starting at a dose of 0.5mg or even 1.7mg of Wegovy, depending on tolerability and side effect history with Mounjaro. However, the standard approach is often to begin at the lowest available dose.

Your clinical history on Mounjaro is the most critical factor:

• If you tolerated Mounjaro well with minimal side effects: Your clinician might proceed with a standard titration schedule for Wegovy.
• If you experienced notable side effects like nausea or fatigue: A more conservative approach is warranted. In this scenario, you will likely start on the lowest Wegovy dose (0.25mg) to introduce the new medication as gently as possible.

The primary objective is to ensure a smooth transition. Starting at a low dose and titrating upwards gradually is standard clinical practice designed to prioritise patient comfort and safety.

The Practical Steps of Making the Switch

For many patients in the UK, switching from Mounjaro to Wegovy is a logical and cost-effective decision, particularly in light of recent price changes. Medical experts generally advise a 7-day washout period to allow for the clearance of tirzepatide before initiating semaglutide, minimising treatment interruption.

This is pertinent in the UK, where Wegovy is prescribed for a BMI of 30+ (or 27+ with a weight-related comorbidity). Even if Mounjaro has helped reduce your BMI below this threshold, clinicians can typically continue treatment based on your medical history. Clinical trial data for Wegovy's 2.4mg maintenance dose showed an average of 15% total body weight loss in 68 weeks. To learn about eligibility, you can review our guide on how to get Wegovy in the UK.

During your consultation, you and your clinician will establish a clear plan. You will discuss your experience with Mounjaro, confirm your medical details, and agree on the washout period and your starting Wegovy dose.

Once you receive your new medication, the process is straightforward. For instance, if your last Mounjaro dose was on a Monday, you would administer your first Wegovy dose the following Monday. Maintaining the same day of the week can help with adherence. From that point, you will follow the standard Wegovy titration schedule, increasing the dose every four weeks as directed by your clinician until you reach the optimal maintenance dose for you.

Understanding Efficacy, Side Effects, and Results

When considering a switch from Mounjaro to Wegovy, it is natural to have questions about expected outcomes. Will the results be comparable? Are the side effects different? The answers can be found by examining the clinical evidence for each medication.

While both are GLP-1 receptor agonists, their mechanisms of action differ. Mounjaro is a dual-agonist, targeting both the GIP and GLP-1 receptors. Wegovy is a single-agonist, acting solely on the GLP-1 receptor. This pharmacological difference can influence both efficacy and individual response.

A Head-to-Head Look at Clinical Trial Data

To obtain a clear, evidence-based understanding of what to expect, we can review the data from large-scale clinical trial programs: the SURMOUNT program for Mounjaro (tirzepatide) and the STEP program for Wegovy (semaglutide). These trials provide robust data on achievable outcomes under controlled conditions.

Presenting these findings side-by-side helps to set clear expectations and allows for a fair comparison of their weight loss potential.

Clinical Trial Outcomes: Mounjaro vs Wegovy

This table summarises the headline results from the major clinical trial programmes for both medications, offering a snapshot of their efficacy under trial conditions.

Based on these data, Mounjaro's dual-agonist action is associated with a higher average weight loss in its key clinical trial. However, it is vital to contextualise these figures. An average weight loss of 15% with Wegovy is a clinically significant and often life-changing outcome.

It is also important to note that the field of GLP-1 treatments is evolving. By early 2026, UK data showed widespread use, with an estimated 1.6 million adults having used these treatments in the previous year. While Wegovy's current 2.4mg dose yields an average 15% weight loss over 68 weeks, a higher dose of 7.2mg is under investigation. Early data for this higher dose has suggested an average weight loss of up to 21%, with 33% of trial participants achieving a 25% or greater reduction in body weight.

These findings suggest that higher doses of semaglutide may produce efficacy results comparable to those of tirzepatide. You can explore more on the growing use of these treatments in research on GLP-1 adoption in the UK.

Managing Side Effects During the Transition

Side effects are a common consideration with any new medication, including during a switch. Because both Mounjaro and Wegovy act on the GLP-1 receptor and affect the digestive system, they share a similar side effect profile.

Common side effects include:

• Nausea
• Diarrhoea or constipation
• Vomiting
• Indigestion or acid reflux
• Fatigue

Even if side effects were minimal on Mounjaro, they may be experienced temporarily as the body adjusts to Wegovy. This is a normal part of the adjustment period, and these effects typically diminish as the dose is titrated.

Key Takeaway: Your previous experience on Mounjaro is a useful predictor. Good tolerability of Mounjaro suggests a higher likelihood of a smooth adaptation to Wegovy. If you experienced significant side effects, your clinician will likely recommend a more cautious, slower titration schedule to help manage any potential discomfort.

This is where a comprehensive support programme can be beneficial. Services that combine medication with expert guidance on nutrition and lifestyle can make a significant difference. Simple strategies—such as eating smaller meals, avoiding high-fat foods, and ensuring adequate hydration—are highly effective for managing side effects. For a more detailed breakdown, you can read our guide on managing weight loss medication side effects. This type of holistic support helps individuals adhere to their treatment plan to achieve the best possible outcomes.

A Holistic Approach for Sustainable Weight Management

Successfully switching from Mounjaro to Wegovy is an important step, but it is essential to recognise that medication is only one component of a comprehensive weight management strategy. For sustainable success, an approach that integrates evidence-based medicine with essential lifestyle modifications is recommended.

Long-term health is not achieved through appetite suppression alone. It requires building a foundation of positive habits that support the body, help maintain muscle mass, and mitigate the risk of weight regain.

More Than Just a Prescription

While GLP-1 medications like Wegovy are highly effective at reducing appetite and "food noise," they are most effective when used within a structured support system. The medication can be viewed as a tool that facilitates behavioural change, but healthy habits are crucial for long-term maintenance.

A comprehensive programme typically combines a prescription with several key elements:

• Expert Clinical Guidance: Regular follow-ups with clinicians who can monitor progress and make informed adjustments to treatment.
• Tailored Nutrition Advice: Practical guidance on dietary choices to manage side effects, optimise energy levels, and support fat loss while preserving lean mass.
• Strength-Focused Exercise: A realistic plan designed to help build and maintain metabolically active muscle mass during weight loss.

This integrated approach helps transform a medication-supported weight loss phase into a sustainable lifestyle change, empowering individuals to navigate the transition and build long-term resilience.

The Critical Role of Preserving Muscle

During weight loss, particularly rapid weight loss, the body can lose lean muscle mass in addition to fat. This is a concern because muscle is metabolically active, contributing to the body's resting metabolic rate. Significant muscle loss can slow metabolism, making further weight loss more difficult and increasing the likelihood of weight regain.

For this reason, incorporating strength training is important. Resistance exercise signals the body to preserve muscle tissue while utilising fat stores for energy.

Preserving muscle mass during weight loss is a key strategy for preventing weight regain. A higher proportion of muscle mass supports a higher metabolism, which is essential for maintaining results after reaching a target weight.

A well-rounded fitness plan does not need to be overly complex. It can include activities like using dumbbells, resistance bands, or bodyweight exercises. As part of a holistic approach, integrating fitness and strength training is crucial; a personalised fitness app like GrabGains can help in tailoring a workout routine to specific needs and goals.

Building Lasting Habits for the Future

The ultimate goal of any weight management programme is to achieve a healthier weight that can be maintained for life. Medication is a powerful tool, but the healthy habits developed during treatment are what ensure long-term success.

Ongoing support from a team of experts, including clinicians and nutritionists, can be invaluable for navigating challenges and maintaining motivation.

Consider these scenarios:

• Managing a Weight Plateau: A support team can help analyse dietary and activity patterns to identify adjustments that can help overcome a plateau.
• Handling Social Events: Nutritional guidance can provide strategies for making healthy choices in social settings without feeling deprived.
• Staying Active When Busy: A coach can help find practical ways to incorporate exercise into a demanding schedule.

A continuous support system is designed to equip individuals with the knowledge and confidence to manage their health independently in the long run. By integrating medication with nutrition, exercise, and expert guidance, individuals are not just losing weight—they are fundamentally improving their relationship with food, physical activity, and overall well-being. This comprehensive approach is key to achieving sustainable weight management success.

Frequently Asked Questions

Considering a switch from Mounjaro to Wegovy is a significant decision, and it is normal to have questions. This section provides clear, clinician-informed answers to common queries from UK patients considering this transition.

Can I Switch to Wegovy if Mounjaro Got My BMI Below the Starting Limit?

This is a frequent and important question. The answer is typically yes.

In the UK, Wegovy is licensed for initiation in patients with a Body Mass Index (BMI) of 30 or higher, or 27 or higher with a weight-related health condition. However, if Mounjaro treatment has been effective and your BMI is now below this threshold, you are not usually disqualified from switching.

Clinicians assess the overall clinical picture. They understand that discontinuing treatment often leads to weight regain.

Your clinician will consider your complete medical history: your starting weight and BMI, the progress you have achieved, and your overall health. The decision will be based on a long-term health strategy, focusing on maintaining your progress and preventing weight regain.

The switch is viewed as a continuation of successful therapy rather than the initiation of a new one. Your prescriber can justify the switch as a necessary step for continuity of care and sustained weight management.

How Will My Clinician Decide My Starting Dose of Wegovy?

This is a critical aspect of a safe transition and is not a direct dose conversion. Your clinician will use your clinical history with Mounjaro to determine a safe starting plan for Wegovy. The approach is cautious to minimise potential side effects.

• A low starting dose is standard. In nearly all cases, you will begin Wegovy at its lowest dose of 0.25mg, regardless of your final Mounjaro dose. This allows your body to acclimatise to semaglutide (the active ingredient in Wegovy).

• Tolerability guides the titration pace. If you tolerated Mounjaro well with few side effects, you will likely follow the standard Wegovy titration schedule, increasing the dose every four weeks (0.25mg, 0.5mg, 1.0mg, 1.7mg, 2.4mg).

• A slower titration for sensitivity. If you experienced side effects like nausea with Mounjaro, your clinician may recommend a slower titration. This could involve remaining on a lower dose of Wegovy for longer than four weeks before increasing it, allowing your body more time to adjust. This safety-first approach helps ensure a smoother transition.

What’s the Current UK Cost Difference Between Mounjaro and Wegovy?

For many individuals, the significant cost difference is a primary factor in considering a switch. Following a price increase for Mounjaro in late 2025, the financial gap between the two treatments widened.

While exact prices can vary between pharmacies, the general price structure is:

• Wegovy: A one-month supply typically ranges from approximately £85 for the initial dose to around £170-£200 for the 2.4mg maintenance dose.
• Mounjaro: Following the price changes, higher doses can cost over £325 per month.

This means switching could result in savings of over £100 per month, depending on the dose. Over a year, this can amount to a substantial sum, making Wegovy a more financially sustainable option for long-term weight management for many in the UK.

Will I Get ‘Food Noise’ Back During the Washout Period?

This is a valid concern. A key benefit of these medications is their ability to reduce "food noise"—the persistent, intrusive thoughts about food. A short "washout" period of approximately 7 days is recommended between the last Mounjaro injection and the first Wegovy injection for a safe transition.

During that week, it is possible to experience a temporary increase in appetite as the effects of Mounjaro diminish. However, for most people, this effect is mild and short-lived. Since the washout period is only a week, the body does not fully revert to its pre-medication state.

Any rebound hunger is typically manageable for this short duration. Once you begin Wegovy, its appetite-suppressing effects will start to take hold, and the feeling of control should return as you titrate up to your effective dose.

At Trim, we understand that navigating a weight management journey involves important decisions. Our UK-registered clinicians provide expert guidance and support at every stage, from initiating treatment to making a switch. We combine medically-proven treatments with personalised support to help you achieve sustainable results safely. Find out if you're eligible for treatment today.